Pharma stocks under pressure as Trump plans executive order to lower drug prices
The Trump administration is definitely on a low prices kick this morning (or at least, prices-not-as-high-as-they-could’ve-been).
But while most of the market is cheering because the US and China have slashed tariffs on one another, there’s one pocket within stocks that is coming under selling pressure because of a separate push to reduce prices paid by US consumers: healthcare stocks, and pharma companies in particular. This typically defensive sector was probably going to be a laggard in any event amid Monday’s broad risk-on tone, but has an extra headwind to grapple with.
On Sunday, President Donald Trump said he would be instituting a “most favored nations” policy with regard to drug prices, tying the US government’s purchase prices to those paid by other nations, and claimed on Monday that this measure would reduce prices by 59%.
The likes of Novo Nordisk and Johnson & Johnson are down in early trading, but well off their lows of the premarket.